OakChart

Solventum Corp

SOLVHealthcare·Medical Instruments & Supplies·USA·Large·NYSE·Nov 11 • 9:45 AM ET

89.91-0.17 (-0.19%)
2026-11-11 15:45 CET
Market cap
15,290.09 USD m
Revenue, TTM
8,163.00 USD m
Net income, TTM
156.00 USD m
Free cash flow, TTM
0.00 USD m
EPS diluted, TTM
0.89
P/E
100.66
Compare

Price

SOLV against its 20, 50 and 200-day averages
2050200miss
70.0080.0090.006.4M12.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SOLVclose 89.9120-day 86.3550-day 87.67200-day 78.7389.91

4.5% under 94.16 on 1 Sep 2026. Last 15 sessions, 15.3% high to low

Profile

SOLV
52-week range, 87% of the way up
62.3894.16

Solventum Corp. operates as a health care company. It gives better, smarter, safer healthcare to improve lives. The company was founded on January 24, 2023 and is headquartered in Maplewood, MN.

IndexS&P 500, RUI
Employees20000
IPOMar 26, 2024
Beta0.69
ATR, 14d2.90
Rel volume0.10
Short float3.51%
Insider own15.33%
Inst own76.97%

Snapshot

6 groups

Valuation

IndexS&P 500, RUI
Market Cap15.26B
Enterprise Value20.08B
Income156.00M
Sales8.16B
Book/sh28.27
Cash/sh2.66
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees20000
IPOMar 26, 2024

Ratios

P/E100.66
Forward P/E11.82
PEG1.07
P/S1.87
P/B3.18
P/C33.84
P/FCF-
EV/EBITDA17.08
EV/Sales2.46
Quick Ratio0.72
Current Ratio1.03
Debt/Eq1.10
LT Debt/Eq0.99
Option/ShortYes / Yes

Earnings

EPS (ttm)0.89
EPS next Y7.60
EPS next Q1.77
EPS this Y18.64%
EPS next Y4.90%
EPS next 5Y11.02%
EPS past 3/5Y4.51% 1.23%
Sales past 3/5Y0.79% 0.47%
EPS Y/Y TTM-89.72%
Sales Y/Y TTM-3.09%
EPS Q/Q-100.97%
Sales Q/Q-7.01%
EarningsNov 05 AMC
EPS/Sales Surpr.8.02% 0.93%

Ownership

Insider Own15.33%
Insider Trans0.00%
Inst Own76.97%
Inst Trans-1.35%
ROA1.11%
ROE3.19%
ROIC1.63%
Gross Margin55.49%
Oper. Margin8.37%
Profit Margin1.91%
SMA204.12%
SMA502.55%
SMA20014.20%
Trades-

Technical

Shs Outstand169.96M
Shs Float143.72M
Short Float3.51%
Short Ratio4.74
Short Interest5.05M
52W High94.16 -4.51%
52W Low62.38 44.13%
Volatility5.08% 3.23%
ATR (14)2.90
RSI (14)57.87
Beta0.69
Rel Volume0.10
Avg Volume1.07M
Volume9,276

Performance

Perf Week0.63%
Perf Month4.18%
Perf Quarter3.99%
Perf Half Y20.83%
Perf YTD13.47%
Perf Year21.70%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom2.31
Target Price99.82
Prev Close90.08
Price89.91
Change %-0.19%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jul 28, 2026UpgradeUUBSNeutral → Buy$95+5.7%
Jul 09, 2026InitiatedBBMO Capital MarketsMarket Perform$81-9.9%
May 15, 2026InitiatedWWedbushOutperform$94+4.5%
May 14, 2026DowngradeUUBSBuy → Neutral$50-44.4%
Mar 24, 2026InitiatedRRothschild & Co RedburnSell$60-33.3%
Jan 26, 2026UpgradeKKeyBanc Capital MarketsSector Weight → Overweight$97+7.9%
Jan 20, 2026UpgradeMMizuhoNeutral → Outperform$100+11.2%
Dec 02, 2025UpgradeBBTIG ResearchNeutral → Buy$100+11.2%
Oct 01, 2025InitiatedUUBSNeutral$77-14.4%
Sep 11, 2025InitiatedJJefferiesHold$80-11.0%

Peers

Mkt cap
TickerCompanyMkt cap
BDXBecton Dickinson & Co57.94B
MDLNMedline Inc54.76B
BAXBaxter International Inc13.59B
SNNSmith & Nephew plc ADR12.98B
TFXTeleflex Incorporated6.16B
NVSTEnvista Holdings Corp4.13B
XRAYDENTSPLY Sirona Inc1.90B
ICUIICU Medical Inc4.55B
MMSIMerit Medical Systems Inc5.22B
IARTIntegra Lifesciences Holdings Corp1.15B

Insider trading

latest 14 of 37
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Gomez Tammy LChief Human Resources OfficerMay 13 '26Option Exercise0.003,960015,030May 15 04:11 PM
McMillan Wayde D.Chief Financial OfficerMay 13 '26Option Exercise0.009,503053,041May 15 04:11 PM
Harrington Paul SChief Supply Chain OfficerMay 13 '26Option Exercise0.003,960022,130May 15 04:10 PM
Wilcox Mary TChief Accounting OfficerMay 13 '26Option Exercise0.002,37607,632May 15 04:09 PM
Kirberger Marcela A.Chief Legal Affairs OfficerMay 13 '26Option Exercise0.004,488015,492May 15 04:09 PM
Hanson Bryan CChief Executive OfficerMay 13 '26Option Exercise0.0034,3150158,225May 15 04:08 PM
Landucci AmyChief Information OfficerMay 13 '26Option Exercise0.004,422041,905May 15 04:07 PM
Wendell Amy McBrideDirectorApr 30 '26Option Exercise0.003,403010,422May 01 04:31 PM
WEILAND JOHN HDirectorApr 30 '26Option Exercise0.003,40308,947May 01 04:30 PM
Mily ElizabethDirectorApr 30 '26Option Exercise0.003,40309,009May 01 04:30 PM
Wilson Darryl L.DirectorApr 30 '26Option Exercise0.003,40308,947May 01 04:29 PM
MAY KAREN JDirectorApr 30 '26Option Exercise0.003,40308,947May 01 04:29 PM
Harris Bernard A JrDirectorApr 30 '26Option Exercise0.003,40308,947May 01 04:28 PM
EISENBERG GLENN ADirectorApr 30 '26Option Exercise0.003,40308,947May 01 04:28 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VOOVanguard S&P 500 ETFAUM: 1054.75B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
RSPInvesco S&P 500 Equal Weight ETFAUM: 104.94B
VBRVanguard Morningstar Small-Cap Value ETFAUM: 37.76B
IVViShares Core S&P 500 ETFAUM: 871.38B
SPYSPDR S&P 500 ETF TrustAUM: 793.23B
XLVState Street Health Care Select Sector SPDR ETFAUM: 50.35B
DFATU.S. Targeted Value Portfolio-ETF Class Shares-
IWRiShares Russell Mid-Cap ETFAUM: 58.68B

News

latest 14 of 206
  • Top Medical Supply Stock Picks From BTIG (Investing.com)
  • Solventum Falls Short Of The Whisper As ERP Reversal Masks Steady ~4% Underlying Growth And A Third Guidance Raise (Earnings Whispers)
  • Solventum: Q3 Earnings Snapshot (Associated Press)
  • Solventum Reports Third Quarter 2026 Financial Results (PR Newswire)
  • Solventum Faces A Planned Q3 Dip As ERP Pull-In Reverses And Guidance Gap Lingers (Earnings Whispers)
  • Loading…
  • Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata Matrix and Solventum V.A.C. Therapy* (PR Newswire)
  • Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026 (PR Newswire)
  • Solventum to Participate in the 2026 Wells Fargo Healthcare Conference (PR Newswire)
  • Solventum plans software separation to become true medtech company (MedTech Dive) -5.16%
  • Solventum Corp (SOLV) (Q2 2026) Earnings Call Highlights: Strong Growth and Strategic ... (GuruFocus.com)
  • Solventum beats estimates, raises guidance on strong growth (Investing.com)
  • Solventum: Q2 Earnings Snapshot (Associated Press)
  • Solventum Reports Second Quarter 2026 Financial Results (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-051.4501.342-0.0701,9491,93111
2026Q22026-08-052.5501.9050.5312,2092,15413
2026Q12026-05-051.4801.3530.0742,0071,96710
2025Q42026-02-261.5701.4950.3591,9981,96211
2025Q32025-11-061.5001.4307.2182,0962,05612
2025Q22025-08-071.6901.4500.5142,1612,11910
2025Q12025-05-081.3401.2110.7842,0702,0169
2024Q42025-02-271.4101.3140.1722,0742,0518
2024Q32024-11-071.6401.3940.7022,0822,0568
2024Q22024-08-081.5601.5050.5132,0812,0494
2024Q12024-05-092.0801.7451.3722,0161,9662
2026Q4--1.772--2,08611
2027Q1--1.766--2,0837
2027Q2--2.020--2,2197
2027Q3--1.863--2,0877
2027Q4--1.982--2,1746

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY8.870-7.7938,230-
2024FY6.7006.5852.7588,2548,232
2025FY6.1106.0318.8808,3258,255
2026FY-7.249--8,252
2027FY-7.604--8,568
2028FY-8.361--8,925
2029FY-8.944--9,281
2030FY-11.180--9,623

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0611122,0862,0632,102
2026Q4S2026-11-0511002,0892,0642,103
2026Q4S2026-10-2111002,0892,0642,103
2026Q4S2026-10-2011102,0882,0612,103
2026Q4S2026-10-1211402,0882,0612,103
2026Q4S2026-10-0911402,0882,0612,103
2026Q4S2026-09-2211402,0892,0612,103
2026Q4S2026-09-1412402,0892,0612,103
2026Q4S2026-09-1012402,0892,0612,103
2026Q4S2026-09-0112402,0892,0612,103
2026Q4S2026-08-2412402,0892,0612,103
2026Q4S2026-08-2312402,0892,0612,103
2026Q4S2026-08-1912502,0892,0612,103
2026Q4S2026-08-1412502,0892,0612,103

Estimate history

EPS, annual8.4547.7767.7932.7588.8760.8932
Period20212022202320242025TTM
EPS, quarterly0.7020.1720.7840.5147.2180.3590.0740.531-0.07
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual817181308197825483258163
Period20212022202320242025TTM
Sales, quarterly208220742070218320961998200722091949
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual172.71172.71172.71172.786173.491169.957
Period20212022202320242025MRQ
Shares, quarterly172.754172.786173.008173.387173.44173.491173.532170.114169.957
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue8,163.008,325.008,254.008,197.008,130.008,171.00
Cost of Goods Sold Incl. D&A3,633.003,864.003,642.003,504.003,435.003,248.00
Gross Profit4,530.004,461.004,612.004,693.004,695.004,923.00
Selling, General and Administrative Excl. Other3,847.003,742.003,514.003,001.003,002.003,044.00
Research and Development712.00727.00768.00758.00767.00766.00
Other Operating Expense0.000.000.000.000.000.00
Operating Income683.00719.001,098.001,692.001,693.001,879.00
Interest Expense233.00347.00367.000.000.000.00
Unusual Expense280.00169.0062.000.000.000.00
Net Income Before Taxes171.001,713.00605.001,667.001,692.001,882.00
Income Taxes14.00157.00126.00321.00349.00422.00
Consolidated Net Income156.001,556.00479.001,346.001,343.001,460.00
Net Income From Continuing Operations156.001,556.00479.001,346.001,343.001,460.00
Net Income156.001,556.00479.001,346.001,343.001,460.00
EPS (Recurring)2.069.553.017.797.788.45
EPS (Basic, Before Extraordinaries)0.908.942.777.797.788.45
EPS (Diluted)0.898.882.767.797.788.45
EBITDA1,176.001,208.001,628.002,253.002,271.002,476.00
Non-Operating Income (Expense)-1.001,509.00-64.00-25.00-1.003.00
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense142.00139.0094.00---
Price To Earnings Ratio100.85100.85----
Price To Sales Ratio1.841.671.39---
Gross Margin55.4953.5955.8857.2557.7560.25
Operating Margin8.378.6413.3020.6420.8223.00
Net Margin1.9118.695.8016.4216.5217.87
Shares Outstanding169.96173.49172.79172.71172.71172.71
Market Capitalization15,290.0915,290.0911,412.3311,410.60--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1,949.002,209.002,007.001,998.002,096.002,183.002,070.002,074.00
Cost of Goods Sold Incl. D&A877.00918.00907.00931.00966.00791.00932.00908.00
Gross Profit1,072.001,291.001,100.001,067.001,130.001,392.001,138.001,166.00
Selling, General and Administrative Excl. Other923.001,072.00976.00876.00959.00892.00954.00983.00
Research and Development180.00178.00186.00168.00183.00184.00190.00199.00
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income149.00219.00124.00191.00171.00500.00184.00183.00
Interest Expense56.0064.0062.0051.0089.00103.00104.00107.00
Unusual Expense95.0042.0040.00103.0084.00286.0032.0047.00
Net Income Before Taxes-11.00108.0016.0058.001,514.00103.0038.0013.00
Income Taxes1.0015.003.00-5.00248.0013.00-99.00-17.00
Consolidated Net Income-12.0092.0013.0063.001,266.0090.00137.0030.00
Net Income From Continuing Operations-12.0092.0013.0063.001,266.0090.00137.0030.00
Net Income-12.0092.0013.0063.001,266.0090.00137.0030.00
EPS (Recurring)0.320.700.230.777.551.660.910.36
EPS (Basic, Before Extraordinaries)-0.070.530.070.367.260.520.790.17
EPS (Diluted)-0.070.530.070.367.220.510.780.17
EBITDA277.00345.00252.00302.00285.00622.00313.00331.00
Non-Operating Income (Expense)-9.00-5.00-7.0020.001,516.00-8.00-11.00-16.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense37.0031.0042.0032.0035.0028.0044.0020.00
Price To Earnings Ratio100.859.457.369.1233.6334.9527.56-
Price To Sales Ratio1.841.611.381.671.521.581.601.40
Gross Margin55.0058.4454.8153.4053.9163.7754.9856.22
Operating Margin7.649.916.189.568.1622.908.898.82
Net Margin-0.624.160.653.1560.404.126.621.45
Shares Outstanding169.96170.11173.53173.49173.44173.39173.01172.79
Market Capitalization15,290.0913,360.4511,329.0913,744.0212,657.3213,121.3113,155.1511,412.33

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments878.00762.00194.0061.00-
Short Term Receivables1,184.001,229.001,313.001,171.00-
Inventories1,066.00965.00857.00873.00-
Other Current Assets731.00293.00155.00126.00-
Total Current Assets3,859.003,249.002,519.002,231.00-
Net Property, Plant & Equipment1,540.001,798.001,555.001,413.00-
Total Investments and Advances1.0016.000.000.00-
Intangible Assets8,296.008,921.009,437.009,686.00-
Deferred Tax Assets--320.00153.00-
Other Assets598.00473.00112.00111.00-
Total Assets14,294.0014,457.0013,943.0013,594.00-
Short Term Debt Incl. Current Port. of LT Debt70.00287.0029.0027.00-
Accounts Payable687.00618.00477.00348.00-
Income Tax Payable196.00122.00---
Other Current Liabilities2,183.001,676.001,222.00936.00-
Total Current Liabilities3,136.002,703.001,728.001,311.00-
Long Term Debt5,177.007,896.0069.0068.00-
Provision for Risks Charges412.00350.00166.0091.00-
Deferred Tax Liabilities164.00225.00231.00215.00-
Other Liabilities356.00324.0083.00167.00-
Total Liabilities9,245.0011,498.002,277.001,852.00-
Non-Equity Reserves0.000.000.000.00-
Preferred Stock - Carrying Value0.000.000.000.00-
Common Equity5,049.002,959.0011,666.0011,742.00-
Total Shareholders Equity5,049.002,959.0011,666.0011,742.00-
Accumulated Minority Interest0.000.000.000.00-
Total Equity5,049.002,959.0011,666.0011,742.00-
Total Liabilities & Stockholders Equity14,294.0014,457.0013,943.0013,594.00-
Book Value Per Share29.1017.1367.5567.99-
Tangible Book Value Per Share-18.72-34.5112.9111.90-
Full-Time Employees20,00022,00022,000--
Price to Book Ratio3.193.583.57--
Return on Assets10.823.379.78--
Return on Equity38.866.5511.50--
Return on Invested Capital15.224.4111.4711.37-
Quick Ratio0.890.840.961.04-
Current Ratio1.231.201.461.70-

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income156.001,556.00479.001,346.001,343.001,460.00
Depreciation521.00489.00555.00561.00578.00597.00
Other Funds (Non Cash)165.00-1,437.00146.0024.00101.00112.00
Funds from Operations630.00488.001,025.001,789.001,881.002,135.00
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-320.00-119.00160.00126.00-202.0067.00
Cash from Operating Activities310.00369.001,185.001,915.001,679.002,202.00
Capital Expenditures-310.00-379.00-380.00-290.00-251.00-277.00
Net Assets From Acquisitions-696.00-696.000.000.000.000.00
Sale of Fixed Assets and Businesses20.003,890.000.0060.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses-6.00-18.000.000.00-2.00-1.00
Other Sources3.000.000.000.000.000.00
Cash from Investing Activities-989.002,797.00-380.00-230.00-253.00-278.00
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock-403.000.000.000.000.000.00
Repurchase of Common Pref Stock-403.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-54.00-3,070.008,003.000.000.000.00
Change in Long Term Debt-54.00-3,070.008,003.000.000.000.00
Issuance of Long Term Debt46.000.008,303.000.000.000.00
Reduction of Long Term Debt-100.00-3,070.00-300.000.000.000.00
Net Financing Active Other Cash Flow-59.0013.00-8,243.00-1,552.00-1,460.00-1,960.00
Other Financing Activities Uses-58.00-33.00-8,251.00-1,553.00-1,460.00-1,960.00
Cash from Financing Activities-516.00-3,057.00-240.00-1,552.00-1,460.00-1,960.00
Exchange Rate Effect2.007.003.000.004.003.00
Net Change in Cash-1,193.00116.00568.00133.00-30.00-33.00
Free Cash Flow0.00-10.00805.001,625.001,428.001,925.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Price to Free Cash Flow--14.25---
Deferred Taxes & Investment Tax Credit--120.00-155.00-142.00-141.00-34.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments451.00403.00561.00878.001,642.00492.00
Short Term Receivables1,391.001,432.001,180.001,184.001,176.001,255.00
Inventories1,102.001,040.001,089.001,066.001,049.00962.00
Other Current Assets750.00865.00754.00731.00540.00499.00
Total Current Assets3,692.003,741.003,583.003,859.004,407.003,208.00
Net Property, Plant & Equipment1,775.001,753.001,729.001,540.001,336.001,313.00
Total Investments and Advances7.004.005.001.000.000.00
Intangible Assets8,170.008,034.008,123.008,296.007,483.007,576.00
Deferred Tax Assets380.00344.00303.00---
Other Assets140.00368.00354.00598.00747.002,977.00
Total Assets14,165.0014,243.0014,097.0014,294.0013,973.0015,074.00
Short Term Debt Incl. Current Port. of LT Debt507.00506.00505.0070.000.000.00
Accounts Payable808.00701.00699.00687.00669.00643.00
Income Tax Payable131.00176.00170.00196.00212.00117.00
Other Current Liabilities2,129.002,280.001,972.002,183.002,057.001,860.00
Total Current Liabilities3,575.003,663.003,346.003,136.002,938.002,620.00
Long Term Debt4,767.004,780.004,782.005,177.005,137.007,815.00
Provision for Risks Charges355.00358.00360.00412.00306.00354.00
Deferred Tax Liabilities154.00157.00161.00164.00169.00231.00
Other Liabilities508.00486.00478.00356.00437.00409.00
Total Liabilities9,359.009,444.009,127.009,245.008,987.0011,429.00
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity4,805.004,800.004,969.005,049.004,986.003,645.00
Total Shareholders Equity4,805.004,800.004,969.005,049.004,986.003,645.00
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity4,805.004,800.004,969.005,049.004,986.003,645.00
Total Liabilities & Stockholders Equity14,164.0014,244.0014,096.0014,294.0013,973.0015,074.00
Book Value Per Share28.2728.2228.6329.1028.7521.02
Tangible Book Value Per Share-19.80-19.01-18.18-18.72-14.40-22.67
Full-Time Employees---20,000--
Price to Book Ratio3.192.692.242.763.474.02
Return on Assets1.119.7810.0110.8210.612.56
Return on Equity3.1933.9634.8038.8637.2511.64
Return on Invested Capital-0.130.960.130.6212.510.79
Quick Ratio0.720.740.750.891.140.86
Current Ratio1.031.021.071.231.501.22

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-12.0092.0013.0063.001,266.0090.00
Depreciation136.00133.00135.00117.00121.00122.00
Other Funds (Non Cash)53.0054.0064.00-6.00-1,546.0051.00
Funds from Operations126.00232.00171.00101.00-29.00230.00
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital51.00-5.00-360.00-6.00105.00-61.00
Cash from Operating Activities177.00227.00-189.0095.0076.00169.00
Capital Expenditures-80.00-83.00-84.00-63.00-97.00-110.00
Net Assets From Acquisitions0.000.000.00-696.000.000.00
Sale of Fixed Assets and Businesses0.000.000.0020.003,870.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.00-6.00-7.000.00
Other Sources0.00-4.007.000.000.000.00
Cash from Investing Activities-80.00-87.00-77.00-745.003,766.00-110.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-48.00-288.00-67.000.000.000.00
Repurchase of Common Pref Stock-48.00-288.00-67.000.000.000.00
Sale of Common Pref Stock0.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.0046.00-100.00-2,770.00-100.00
Change in Long Term Debt0.000.0046.00-100.00-2,770.00-100.00
Issuance of Long Term Debt0.000.0046.000.000.000.00
Reduction of Long Term Debt0.000.000.00-100.00-2,770.00-100.00
Net Financing Active Other Cash Flow-2.00-13.00-29.00-15.0077.00-10.00
Other Financing Activities Uses-2.00-13.00-31.00-12.0028.00-10.00
Cash from Financing Activities-51.00-300.00-50.00-115.00-2,693.00-110.00
Exchange Rate Effect0.003.00-2.001.00-1.006.00
Net Change in Cash46.00-157.00-318.00-764.001,148.00-45.00
Free Cash Flow97.00144.00-273.0032.00-21.0059.00
Price to Free Cash Flow----256.0890.39

Revenue breakdown

Cost Of Software And Rentals2024: 1.91B 2025: 1.98B
Product2024: 6.35B 2025: 6.35B
Non-US2024: 3.70B 2025: 3.66B
United States2024: 4.56B 2025: 4.67B
Consolidation, Policy2024: 307.00M 2025: 302.00M
Dental Solutions2024: 1.30B 2025: 1.35B
Health Information Systems2024: 1.31B 2025: 1.36B
MedSurg2024: 4.64B 2025: 4.82B
Purification and Filtration2024: 709.00M 2025: 497.00M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.51%5.0M143.7M1.04M
2026-10-153.44%5.0M144.1M1.06M
2026-09-303.39%4.9M144.6M1.04M
2026-09-153.36%4.9M144.6M1.16M
2026-08-312.97%4.3M144.6M1.31M
2026-08-142.40%3.5M144.6M1.59M
2026-07-312.43%3.5M144.6M1.68M
2026-07-152.92%4.3M147.1M1.66M
2026-06-303.42%5.0M147.1M1.73M
2026-06-153.70%5.4M147.0M1.70M
2026-05-295.15%7.6M147.1M1.63M
2026-05-155.37%7.9M147.1M1.42M
2026-04-304.40%6.5M147.2M1.28M
2026-04-154.33%6.4M147.5M1.27M
2026-03-313.65%5.4M147.6M1.22M
2026-03-132.69%4.0M147.6M1.13M
2026-02-272.36%3.5M147.6M1.07M
2026-02-132.40%3.5M147.6M1.06M
2026-01-302.48%3.7M147.6M1.09M
2026-01-152.48%3.7M147.6M1.04M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call40.000.000.000.00-0.000.00---
call45.000.000.000.00-0.000.00---
call50.000.000.000.00-0.000.00---
call55.000.000.000.00-0.000.00---
call60.000.000.0023.58-5.000.00---
call65.000.000.000.00-0.000.00---
call70.000.000.0018.72-5.000.00---
call75.000.000.0015.50-11.000.00---
call80.000.000.005.59-81.000.00---
call85.000.000.005.80-1590.00---
call90.000.000.002.00-7810.00---
call95.000.000.000.55-4450.00---
call1000.000.000.14-5440.00---
call1050.000.000.14-1,5340.00---
call1100.000.001.08-2.000.00---
call1150.000.000.05-6.000.00---
call1200.000.000.25-1.000.00---
call1250.000.000.32-6.000.00---
call1300.000.000.00-0.000.00---
call1350.000.000.75-2.000.00---
put40.000.000.000.00-0.000.00---
put45.000.000.000.00-0.000.00---
put50.000.000.000.00-0.000.00---
put55.000.000.000.90-1.000.00---
put60.000.000.000.22-5.000.00---
put65.000.000.001.53-6.000.00---
put70.000.000.001.50-3.000.00---
put75.000.000.000.10-1,1250.00---
put80.000.000.000.20-83.000.00---
put85.000.000.000.50-2,1750.00---
put90.000.000.001.87-53.000.00---
put95.000.000.004.50-36.000.00---
put1000.000.0011.30-0.000.00---
put1050.000.0013.00-0.000.00---
put1100.000.0024.18-0.000.00---
put1150.000.000.00-0.000.00---
put1200.000.000.00-0.000.00---
put1250.000.000.00-0.000.00---
put1300.000.000.00-0.000.00---
put1350.000.000.00-0.000.00---

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-183Initial statement of beneficial ownership of securities2026-08-10SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-208-KCurrent report2026-07-16SEC
2026-06-058-KCurrent report2026-06-02SEC
2026-05-29SDSpecialized Disclosure ReportSEC
2026-05-278-KCurrent report2026-05-21SEC
2026-05-208-KCurrent report2026-05-15SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-15SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-15SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-15SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-15SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-15SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-15SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-15SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-15SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-15SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-15SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-15SEC
2026-05-154Statement of changes in beneficial ownership of securities2026-05-13SEC
2026-05-154Statement of changes in beneficial ownership of securities2026-05-13SEC
2026-05-154Statement of changes in beneficial ownership of securities2026-05-13SEC
2026-05-154Statement of changes in beneficial ownership of securities2026-05-13SEC
2026-05-154Statement of changes in beneficial ownership of securities2026-05-13SEC
2026-05-154Statement of changes in beneficial ownership of securities2026-05-13SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-03100.34K100
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Independent Franchise Partners LLP9.34%
BlackRock, Inc.5.64%
VANGUARD CAPITAL MANAGEMENT LLC5.56%
TRIAN FUND MANAGEMENT, L.P.4.76%
DAVIS SELECTED ADVISERS3.77%
VANGUARD PORTFOLIO MANAGEMENT LLC3.65%
STATE STREET CORP3.26%
GEODE CAPITAL MANAGEMENT, LLC2.91%
Boston Partners2.10%
Invesco Ltd.1.91%

Funds

Fund% owned
Baird Ultra Short Bond Fund32.55%
VANGUARD INTERMEDIATE-TERM CORPORATE BOND INDEX FUND27.44%
Baird Aggregate Bond Fund24.93%
Janus Henderson Balanced Fund23.08%
JPMorgan Core Bond Fund21.96%
Bond Fund21.12%
Baird Core Plus Bond Fund20.58%
T. Rowe Price New Income Fund, Inc.18.18%
First Trust Enhanced Short Maturity ETF17.67%
Bridge Builder Core Bond Fund12.32%

OakChart. SOLV. Cached 15 minutes.